The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That’s when V. Michael Holers, MD, a University of Colorado School of Medicine professor with a focus on autoimmune diseases; Joshua Thurman, MD, a CU School of Medicine nephrologist; and Medical University of South Carolina immunologist Stephen Tomlinson, PhD, started collaborating.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
